IP Library Granted Patent US 11,446,523
Granted Patent B2
US 11,446,523 · App. 16/833,637 · Granted Sep 20, 2022

Compositions, methods and systems for gas vesicle based cavitation

Inventors: Avinoam D. Bar-Zion (Pasadena, CA); Atousa Nourmahnad (Villanova, PA); David Maresca (Pasadena, CA); Mikhail Shapiro (Pasadena, CA)
Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
A61N7/00A61N2007/0004A61N2007/0039A61N2007/0052A61N2007/0082
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,446,523
App. No.
16/833,637
Granted
Sep 20, 2022
Kind
B2
Abstract

The system and process of therapeutic and effective cavitation by using ultrasound to collapse gas vesicles as well as cavitate the bubbles produced from the collapsed gas vesicles. Therapeutic effect includes, but is not limited to lysing cells by cavitation. The cells expressing the gas vesicles can optionally be used as delivery cells to preform tasks such as transporting the gas vesicles into deep tissue areas, releasing compounds at the cavitation site, and more. The gas vesicles can optionally be modified to facilitate getting the bubbles near the cavitation targets by functionalizing the gas vesicles.

Claims (34)

1. An ultrasound pressure-based method comprising:

delivering a gas vesicle (GV) to a target site, the GV having a GV type collapse threshold pressure;

setting an ultrasound generation system to produce ultrasound pulses having a positive pressure set above the GV type collapse threshold pressure and a negative pressure; and

applying the ultrasound pulses to the target site, thus:

collapsing the GV by the positive pressure of the ultrasound pulses, thereby forming gas bubbles; and

driving cavitation of the gas bubbles by the negative pressure.

2. The method of claim 1 , further comprising imaging the target site before applying the ultrasound pulses.

3. The method of claim 2 , wherein the imaging comprises one of ultrasound imaging or MRI.

4. The method of claim 3 , wherein the imaging comprising using the GV as a contrast agent.

5. The method of claim 2 , further comprising imaging the target site after applying the ultrasound pulses.

6. The method of claim 1 , wherein the ultrasound pulses are applied with a center frequency no greater than 2.5 MHz.

7. The method of claim 6 , wherein the ultrasound pulses have a mechanical index above 0.12.

8. The method of claim 7 , wherein the ultrasound pulses have a mechanical index above 2.8.

9. The method of claim 1 , wherein the GV is a plurality of GVs.

10. A method of applying a mechanical stress to a cavitation target in a target site, the method comprising:

delivering to the target site containing the cavitation target one or more gas vesicles (GVs) having a GV type collapse threshold, the delivering positioning the GVs in proximity of the cavitation target, and

applying ultrasound pulses to the target site after the delivering, the ultrasound pulses having a positive pressure set above the GV type collapse threshold pressure and a negative pressure and being selected to both collapse the GV type and to, by the negative pressure, cavitate bubbles created by the GVs after collapse, the cavitated bubbles applying the mechanical stress to the cavitation target.

11. The method of claim 10 , wherein the cavitation target is an inorganic target.

12. The method of claim 10 , wherein the mechanical stress is selected from the group consisting of destroying, damaging, pushing, pinching, propelling, mixing, and deforming.

13. The method of claim 10 , further comprising imaging the target site at a first time to verify delivery of the GVs at the target site and imaging the target site at a second time to verify an effect of the cavitating of the bubbles.

14. The method of claim 1 , being a method of lysing a target cell of a target tissue at the target site, further comprising lysing the target cell by the cavitated bubbles.

15. The method of claim 1 , wherein the ultrasound pulse has a center frequency selected to be less than 2.5 MHz.

16. The method of claim 15 , wherein the GV are functionalized to attach to tissue at the target site.

17. The method of claim 15 , wherein the delivering the GV to tissue at the target site comprises expressing the GV in a delivery cell that is delivered to the target tissue.

18. The method of claim 15 , wherein the GV contains a payload compound that has a therapeutic effect on tissue at the target site.

19. The method of claim 1 , wherein the delivering the GV to the target site comprises delivering a delivery cell containing the GV, and wherein cavitated bubbles lyse a target cell by lysing the delivery cell.

20. The method of claim 19 , wherein the delivery cell expresses the GV.

21. The method of claim 19 , wherein the delivery cell contains a hybrid cluster.

22. The method of claim 1 , being a method of delivering a payload compound to a target tissue at the target site, wherein the delivering the GV to the target site comprises delivering a delivering cell configured to express the payload compound, the delivering performed for a time and under conditions allowing expression of the GV in the delivery cell, and wherein the cavitated bubbles lyse the delivery cell and deliver the target compound to the target tissue.

23. The method of claim 22 , wherein the target compound is a protein expressed by the delivery cell.

24. The method of claim 22 , wherein the allowing the expression of the GV in the delivery cell occurs before the delivering the delivery cell.

25. The method of claim 22 , further comprising ultrasound imaging or MRI imaging the delivery cell at the target site.

26. The method of claim 22 , wherein the target compound is a therapeutic substance.

27. The method of claim 1 , wherein the ultrasound pulses have at least one of: a duty cycle above 0.2% or a mechanical index above 2.8.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2020
From: HERITAGE MEDICAL RESEARCH INSTITUTE
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 052276/0540 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2020
From: BAR-ZION, AVINOAM D.; NOURMAHNAD, ATOUSA; MARESCA, DAVID
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 052265/0726 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2020
From: SHAPIRO, MIKHAIL
To: CALIFORNIA INSTITUTE OF TECHNOLOGY; HERITAGE MEDICAL RESEARCH INSTITUTE
Reel/Frame 052265/0733 →
Continuity (3)
Provisional Application 62825612 · Mar 28, 2019
Provisional Application 62895553 · Sep 4, 2019
Related Publication 20200306564A1 · Oct 1, 2020
Cited By (2)
US 12,209,268 US 12,370,272